Evecxia Therapeutics Reports Favorable Data From a Phase 1 SAD/MAD Trial
Evecxia Therapeutics, Inc. announced favorable safety, tolerability, pharmacokinetic, and pharmacodynamic data from a double-blind, placebo-controlled Phase 1, a two-part single ascending dose (SAD) and multiple ascending dose (MAD) trial of EVX-101 in healthy volunteers treated with escitalopram. The Company further announced the planned design of a Phase 2 adjunctive EVX-101 trial in patients with major depressive disorder (MDD) responding inadequately to a first-line antidepressant (selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI)).
External URL: https://www.quotientsciences.com/news/evecxia-phase-1-trial/
By Arcinova
447 Views
Recent Posts
- Explore the Impact of Verifying Carbon Capture Technologies
- ITS wins Supplier of the Year at the ISPE UK Affiliate Annual Awards
- Cembre MG4 | The Newest Thermal Printer for Identification & Labelling | Available From Thorne & Derrick
- Share your expertise at ICPVT15: International Conference on Pressure Vessel Technology
- Minimising GWR Probe Build Up with the Magnetrol Eclipse 706
Back to News >
Share this
Most Recent Post
© Copyright. North East of England Process Industry Cluster (NEPIC) 2015
Built by iTCHYROBOT